Back to Search Start Over

Machine Learning Analysis in Diffusion Kurtosis Imaging for Discriminating Pediatric Posterior Fossa Tumors: A Repeatability and Accuracy Pilot Study.

Authors :
Voicu, Ioan Paul
Dotta, Francesco
Napolitano, Antonio
Caulo, Massimo
Piccirilli, Eleonora
D'Orazio, Claudia
Carai, Andrea
Miele, Evelina
Vinci, Maria
Rossi, Sabrina
Cacchione, Antonella
Vennarini, Sabina
Del Baldo, Giada
Mastronuzzi, Angela
Tomà, Paolo
Colafati, Giovanna Stefania
Source :
Cancers. Jul2024, Vol. 16 Issue 14, p2578. 16p.
Publication Year :
2024

Abstract

Simple Summary: Differentiating pediatric posterior fossa (PF) tumors such as medulloblastoma (MB), ependymoma (EP), and pilocytic astrocytoma (PA) remains relevant, due to important treatment and prognostic implications. Diffusion kurtosis imaging (DKI) has not been tested to date to distinguish between pediatric PF tumors. Estimating diffusion values from whole-tumor-based (VOI) segmentations may improve the repeatability of diffusion measurements compared to conventional region-of-interest (ROI) approaches. Our purpose was twofold: to assess the repeatability of VOI DKI-derived diffusion measurements and DKI accuracy in discriminating among pediatric PF tumors, by employing conventional statistical analyses and machine learning (ML) techniques. Background and purpose: Differentiating pediatric posterior fossa (PF) tumors such as medulloblastoma (MB), ependymoma (EP), and pilocytic astrocytoma (PA) remains relevant, because of important treatment and prognostic implications. Diffusion kurtosis imaging (DKI) has not yet been investigated for discrimination of pediatric PF tumors. Estimating diffusion values from whole-tumor-based (VOI) segmentations may improve diffusion measurement repeatability compared to conventional region-of-interest (ROI) approaches. Our purpose was to compare repeatability between ROI and VOI DKI-derived diffusion measurements and assess DKI accuracy in discriminating among pediatric PF tumors. Materials and methods: We retrospectively analyzed 34 children (M, F, mean age 7.48 years) with PF tumors who underwent preoperative examination on a 3 Tesla magnet, including DKI. For each patient, two neuroradiologists independently segmented the whole solid tumor, the ROI of the area of maximum tumor diameter, and a small 5 mm ROI. The automated analysis pipeline included inter-observer variability, statistical, and machine learning (ML) analyses. We evaluated inter-observer variability with coefficient of variation (COV) and Bland–Altman plots. We estimated DKI metrics accuracy in discriminating among tumor histology with MANOVA analysis. In order to account for class imbalances, we applied SMOTE to balance the dataset. Finally, we performed a Random Forest (RF) machine learning classification analysis based on all DKI metrics from the SMOTE dataset by partitioning 70/30 the training and testing cohort. Results: Tumor histology included medulloblastoma (15), pilocytic astrocytoma (14), and ependymoma (5). VOI-based measurements presented lower variability than ROI-based measurements across all DKI metrics and were used for the analysis. DKI-derived metrics could accurately discriminate between tumor subtypes (Pillai's trace: p < 0.001). SMOTE generated 11 synthetic observations (10 EP and 1 PA), resulting in a balanced dataset with 45 instances (34 original and 11 synthetic). ML analysis yielded an accuracy of 0.928, which correctly predicted all but one lesion in the testing set. Conclusions: VOI-based measurements presented improved repeatability compared to ROI-based measurements across all diffusion metrics. An ML classification algorithm resulted accurate in discriminating PF tumors on a SMOTE-generated dataset. ML techniques based on DKI-derived metrics are useful for the discrimination of pediatric PF tumors. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726694
Volume :
16
Issue :
14
Database :
Academic Search Index
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
178701220
Full Text :
https://doi.org/10.3390/cancers16142578